Clinical Trials List
Protocol NumberMK-6482-033
Not yet recruiting
2025-11-01 - 2034-12-31
Phase III
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Tzu-Hao Huang Division of Urology
- 蔡承翰 Division of Urology
- Tzu-Hsiang Hsu Division of Urology
- Yen-Hwa Chang Division of Urology
- 彭昱璟 Division of Others
- Tzu-chun Wei Division of Urology
- 沈書慧 Division of Radiology
- Hsiao-Jen Chung Division of Urology
- Chih-Chieh Lin Division of Urology
- 陳人傑 Division of Urology
Co-Principal Investigator
- Chao-Hsiang Chang Division of Urology
- Yi-Huei Chang Division of Urology
- Yu-De Wang Division of Urology
- Wei-Ching Lin Division of Radiology
- Hsi-Chin Wu Division of Urology
- 蔡禮賢 Division of Urology
- Chi-Rei Yang Division of Urology
- Han Chang Division of Others -
- 方仁愷 Division of Urology
- 邱鴻傑 Division of Urology
Co-Principal Investigator
- I-hung Shao Division of Hematology & Oncology
- 張境夫 Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- Yung-Chia Kao Division of Hematology & Oncology
- Hong-Cheng Gan Division of Hematology & Oncology
- Yung-Chang Lin Division of Hematology & Oncology
- 沈鼎文 Division of Radiology
- 吳俊德 Division of Hematology & Oncology
- See-Tong Pang Division of Hematology & Oncology
- 余紹銘 Division of Hematology & Oncology
- PO-HUNG LIN Division of Hematology & Oncology
Co-Principal Investigator
- Chia-Yen Lin Division of Urology
- 張家程 Division of Urology
- 張瓈文 Division of Urology
- Shian-Shiang Wang Division of Urology
- 賴谷順 Division of Urology
- Cheng-Che Chen Division of Urology
- 梅承恩 Division of Urology
- Cheng-Kuang Yang Division of Urology
- 楊哲瑞 Division of Urology
- Chuan-Shu Chen Division of Urology
- 楊涵中 Division of Urology
- 王樹吉 Division of Urology
- 洪晟鈞 Division of Urology
- 裘坤元 Division of Urology
- 林雁婷 Division of Radiology
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
904 participants